Rius Medical

Cell & Gene Therapy will shape the future of medicine, when novel technologies proceed beyond the primary goals of safety and efficacy. Uneconomical manufacturing represents a major roadblock to the sustainable commercialisation of cellular products.

Rius Medical technology engineers stem cells into therapeutic products. Offering a Business-to-Business solution to U.S. based company Rubius Therapeutics and France-based Erytech Pharma for upgraded red blood cells that do more than simply carry oxygen. For example Erytech Pharma’s therapeutic product is Phase III approved for Acute Lymphoblastic Leukemia and Phase II approved for Pancreatic Cancer.

That’s right, the 700.000 euro Series A investment addressing Business-to-Business solution has emphasis on 12 million euro Return on Investment at 3 years for the early investors.